Palatin Technologies Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
53.8%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$13.7Mnext fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q1 Fiscal Year 2027 Earnings Release (Quarter Ended September 30, 2026) | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly10.2MTarget: Sufficient cash runway beyond the quarter ending December 31, 2026
Collaboration and License Revenue Quarterly3.9MTarget: Continued milestone achievements under Boehringer Ingelheim and Altanispac agreements
Clinical Trial Progression - MC4R Agonist (Obesity) AnnuallyTarget: IND filing for once-weekly peptide MC4R agonist in 4Q 2026
Watch Items
- PL9643 Phase 3 MELODY-2 & MELODY-3 InitiationTrigger: Potential initiation of Phase 3 trials in calendar year 2026Action: Monitor clinical trial registry updates and company press releases for patient enrollment milestones.
- Cash Burn Rate and RunwayTrigger: Cash balance dropping below $5.0 million without a corresponding non-dilutive milestone paymentAction: Evaluate potential dilutive equity financing risks or the need for new out-licensing partnerships.
- Boehringer Ingelheim Retinal Disease Collaboration MilestonesTrigger: Achievement of research or clinical milestones triggering further payments from the $300M+ potential poolAction: Assess non-dilutive funding inflows and validate the therapeutic potential of the melanocortin platform.
Research as of 20 Jun 2026